Skip to main content

Table 4 Small molecule inhibitors

From: Novel and emerging therapies for B cell lymphoma

Drug Class Patient population N ORR CR Grade 3 AE Reference
M7583 BTK inhibitor R/R DLBCL, WM, MCL, MZL, SLL 18 50% 11% Diarrhea [80]
ME-401 PI3Kδ R/R FL, CLL 31 83% NA Diarrhea, rash [81]
LAM-002A Endosomal protein inhibitor R/R DLBCL, MCL, FL, MZL, CLL 24 NA NA Tumor lysis syndrome [82]
INCB057643 BET protein inhibitor R/R FL, DLBCL 5 33% (DE) None Hyperglycemia, thrombocytopenia, anemia, hyperbilirubinemia, Increased INR [83]
MRG-106 miR-155 inhibitor Mycosis fungoides 38 NA NA Pruritus, tumor flare [84]
DS-3201b EZH1/2 dual inhibitor PTL, AITL, DLBCL, FL, MZL 15 53% 6.6% Pneumonia [85]
Apatinib VEGFR-2 tyrosine kinase inhibitor R/R NHL 21 47.6% 9.5% None [86]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, AE adverse events, R/R relapsed and refractory, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MZL marginal zone lymphoma, MCL mantle cell lymphoma, PTL peripheral T cell lymphoma, AITL angio-immunoblastic T cell lymphoma, NHL non-Hodgkin lymphoma, VEGFR-2 vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, PI3Kδ phosphatidylinositol 3 kinase delta, BET bromodomain and extraterminal protein inhibitor, EZH enhancer of zeste homolog, miR micro RN, DE dose escalation phase, NA data unavailable